This redirect is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of
Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join
the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
A member of the Guild of Copy Editors,
Miniapolis, reviewed a version of this article for copy editing on 13 January 2020. However, a major copy edit was inappropriate at that time because of the issues specified below, or the other tags now found on this article. Once these issues have been addressed, and any related tags have been cleared, please tag the article once again for {{
copyedit}}. The Guild welcomes all editors with a good grasp of English. Visit our
project page if you are interested in joining! Please address the following issues as well as any other cleanup tags before re-tagging this article with copyedit: Open merge proposal
No merge
The following discussion is closed. Please do not modify it. Subsequent comments should be made in a new section.A summary of the conclusions reached follows.
Merge@
Graeme Bartlett: Unfortunately, I currently have little confidence in the ability of the creator of this article to utilise
WP:RS to generate usefully constructed content, and have raised this
on their talk page, following an AFD discussion on
another of their creations. Unfortunately, the subject here is beyond my comprehension, but my instinct is to suggest that just a section on inhibitors, based on properly researched references merged from here into the article on
GSK-3 would be better than a stand-alone article, unless, that is, you or another editor are able to apply sufficient expertise to ensure this isn't promotional nonsense or just a semi-scientific essay with a few random references thrown in. (As I draft this response, I note that the article creator has just been indefinitely blocked by
Swarm per
WP:NOTHERE.)
Nick Moyes (
talk)
00:50, 28 December 2018 (UTC)reply
Merge@
Graeme Bartlett: Due to the diversity of potential mechanisms of action, and applications, it seems to me that a section on inhibitors should be (and is) included on
GSK-3, and that the particular mechanisms of action for each Inhibitor should be mentioned on the relevant specific page, with an overview in the GSK-3 Inhibitors section of GSK-3. That is, I feel that the information on GSK-3 inhibitors wouldn't be cohesive enough to form a complete article since all you can do is describe some mechanisms, give examples, and explain the applications. If the article looked more like the article on
MAOI, then I might consider No Merge, but unless that happens, I'd prefer to support a merge.
Direwolf202 (
talk)
18:04, 15 August 2019 (UTC)reply
Merge@
Graeme Bartlett: Upon reviewing this article and
GSK-3, a merge would simplify everything. The benefits section on this article is redundant, and we could supplement the individual medications on the GSK article itself.
Moksha88 (
talk)
03:00, 17 August 2019 (UTC)reply
The discussion above is closed. Please do not modify it. Subsequent comments should be made on the appropriate discussion page. No further edits should be made to this discussion.